본문 바로가기
investors

[Media Releases] [Sanofi]Sanofi decides joint research with LegoChem Biosciences on cadidate substances.

2015.06.26

Title: Sanofi – Sanofi decides joint research with LegoChem Biosciences on cadidate substances.

Publication: Sanofi

Date: 31 July 2012


Summary

  • Will conduct research on candidate substances for drugs that can treat diseases with high prevalence rate among Asians.

  • Expecting win-win partnership between a global pharmaceutical company and domestic venture company based on open-innovation strategy.

 

To view the full article (in Korean), click here 

 

 

About LegoChem Biosciences

 

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).